Vyvanse in Black and African Ancestry Patients: Documented Efficacy Gaps and What the Data Actually Show

Why Race and Ancestry Matter for Lisdexamfetamine Prescribing

Race and ancestry are not the same as biology, but population-level differences in allele frequencies, co-morbidity burden, and historical underrepresentation in clinical trials each affect how a clinician should interpret efficacy and safety signals for any drug. Lisdexamfetamine is a prodrug that relies on enzymatic conversion in the bloodstream. Any genetic or physiological factor that shifts that conversion rate changes the effective dose a patient receives, even when the milligram number on the label stays the same.

Black and African ancestry patients with ADHD face a compounding problem: they are underdiagnosed relative to white peers, underrepresented in the key trials that generated the prescribing label, and carry a higher baseline burden of cardiovascular and metabolic conditions that stimulants can worsen. These are separate issues that converge at the point of the prescription pad.

The Under-Diagnosis Problem

ADHD diagnosis rates in Black children have historically run 30-40% lower than in white children of comparable symptom burden, according to CDC surveillance data reviewed in 2023 [1]. By the time Black patients reach a prescriber, they may have been symptomatic for years without documentation. That gap affects not just treatment timing but the reference populations against which trial efficacy data are compared.

What "Efficacy" Means in This Context

Efficacy gaps can arise from three distinct mechanisms: pharmacokinetic differences (the drug reaches different plasma concentrations), pharmacodynamic differences (the drug acts differently at the receptor), or access-and-adherence differences (the drug is prescribed at subtherapeutic doses or discontinued earlier). Distinguishing these matters because they call for different clinical responses.

How Lisdexamfetamine Is Converted to Active Drug

Lisdexamfetamine itself is pharmacologically inert. After oral absorption, it is hydrolyzed in the bloodstream to l-lysine and d-amphetamine. The enzyme responsible is a peptidase localized primarily to red blood cells [2]. This is a meaningful mechanistic detail because any condition that alters red blood cell number, morphology, or enzyme expression may alter the rate of conversion.

The G6PD Connection

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common inherited enzyme disorder globally, affecting an estimated 400 million people. In individuals of African ancestry, the A-variant (G6PD A-) is present in approximately 10-13% of males and 2-4% of females (given the X-linked inheritance pattern) [3]. G6PD deficiency alters the oxidative environment inside red blood cells and affects membrane integrity under stress.

The prescribing label for Vyvanse does not list G6PD deficiency as a contraindication, and no published RCT has directly measured lisdexamfetamine hydrolysis rates in G6PD-deficient individuals. The theoretical concern is that altered RBC physiology could shift hydrolysis kinetics. Clinicians treating patients known to carry a G6PD-deficient allele should be alert to atypical dose-response curves (either unexpectedly low or unusually prolonged effect) rather than assuming standard titration will apply linearly.

CYP2D6 Pharmacogenomics

Once d-amphetamine is released, it is partially metabolized by CYP2D6 before renal excretion. CYP2D6 is one of the most polymorphic genes in the human genome. The poor-metabolizer phenotype (carrying two loss-of-function alleles such as *4, *5, or *6) results in higher plasma amphetamine concentrations and longer half-life. Population genomics data from PharmGKB and the 1000 Genomes Project show that the CYP2D6 *17 allele, which encodes a reduced-function enzyme, occurs at a frequency of roughly 20-35% in sub-Saharan African populations compared with under 2% in European populations [4]. Patients carrying one or two copies of *17 are classified as intermediate metabolizers. They may sustain higher peak d-amphetamine plasma levels at a given dose than patients with a fully functional CYP2D6 enzyme pair.

This is not a reason to withhold treatment. It is a reason to titrate more slowly (30 mg starting dose, increments of 10 mg rather than 20 mg in patients with a known reduced-function CYP2D6 phenotype) and to monitor blood pressure and heart rate at each step.

What the Clinical Trial Data Actually Show

Wigal et al. (2017): The Most Directly Relevant Pediatric Dataset

The most frequently cited pediatric efficacy analysis is Wigal et al. (J Atten Disord 2017), which examined laboratory school data from earlier key trials of lisdexamfetamine in children aged 6-12 [5]. The primary endpoint was SKAMP-Combined score. The trial enrolled a predominantly white sample; Black participants constituted a small subgroup that was not independently powered for statistical comparison. Race was recorded but efficacy by race was not reported as a pre-specified secondary endpoint.

This means one thing clinically: the absence of a documented gap in that trial is not the same as evidence of no gap. The subgroup was too small to detect a difference of any clinically meaningful size.

Broader Stimulant Trial Enrollment Patterns

A 2021 systematic review of ADHD medication trials published between 2000 and 2020 found that Black participants represented a median of 9.8% of enrolled subjects across 47 trials, against a U.S. Population share of approximately 13.6% [6]. The underrepresentation was more pronounced in pediatric than adult studies. When subgroup analyses were reported at all, they typically lacked the statistical power to detect between-group differences smaller than 15-20% in effect size.

The FDA's own internal review guidance for ADHD drugs does require race stratification in trial design, but the requirement has not consistently translated into adequately powered subgroup analyses in the published literature.

Interpreting Effect Size in the Context of Under-Enrollment

A small enrolled subgroup means wide confidence intervals around any subgroup estimate. A trial reporting "no statistically significant difference by race" when N=40 in the Black subgroup is not reassuring. It is uninformative. The clinical field needs ethnicity-stratified trials with pre-specified, adequately powered endpoints. None exist for lisdexamfetamine as of the date this article was reviewed.

The HealthRX clinical team uses a four-domain framework for evaluating lisdexamfetamine in Black and African ancestry patients: (1) prodrug-conversion risk factors (G6PD status, hemoglobin phenotype), (2) CYP2D6 phenotype when accessible through pharmacogenomic testing, (3) cardiovascular baseline (blood pressure, resting heart rate, family history of early cardiac events), and (4) prior stimulant response history if available. Each domain is assessed before the first prescription and revisited at each titration step.

Cardiovascular Monitoring: A Higher-Stakes Context

Lisdexamfetamine raises heart rate and systolic blood pressure. The prescribing label reports mean increases of approximately 2-4 mmHg in systolic BP and 2-6 bpm in heart rate across key trials. These are average effects in predominantly non-Black trial populations. In a patient who starts with a baseline systolic BP of 135 mmHg rather than 115 mmHg, even a 4 mmHg increase carries different absolute risk implications.

Hypertension Prevalence in Black Adults

The American Heart Association's 2024 Heart Disease and Stroke Statistics report documented that approximately 55% of non-Hispanic Black adults have hypertension, compared with approximately 46% of non-Hispanic white adults [7]. Black adults also experience hypertension onset at younger ages and have higher rates of hypertensive end-organ damage including left ventricular hypertrophy and CKD.

This does not mean stimulants are contraindicated in hypertensive Black patients. It means that pre-treatment blood pressure control should be confirmed (ideally systolic <140 mmHg and diastolic <90 mmHg), and that monitoring frequency should be higher. The American Academy of Pediatrics 2019 ADHD Clinical Practice Guideline recommends blood pressure and heart rate assessment at each medication adjustment visit [8].

CKD and Renal Clearance

Amphetamine is primarily renally excreted. CKD impairs this clearance and increases the effective drug exposure at any given dose. Black patients carry a disproportionate CKD burden partly due to higher hypertension and diabetes rates, and partly due to APOL1 high-risk genotypes (G1 and G2 variants) found almost exclusively in individuals of African ancestry [9]. A patient with eGFR <30 mL/min/1.73m2 may accumulate d-amphetamine more rapidly than a patient with normal renal function at the same nominal dose.

Clinicians should obtain a baseline metabolic panel including creatinine and estimated GFR before initiating lisdexamfetamine in any adult patient, and particularly in Black adults where CKD may be subclinical at presentation.

Dosing Guidance and Titration Considerations

The FDA-approved starting dose of lisdexamfetamine for ADHD is 30 mg orally once daily in the morning, regardless of patient demographics. Maximum approved dose is 70 mg/day. Titration increments are 10-20 mg, adjusted at weekly intervals [10].

When to Consider a Slower Titration Schedule

For Black and African ancestry patients, the HealthRX medical team recommends considering 10 mg increments (rather than 20 mg) between titration steps when any of the following are present:

• Baseline systolic BP above 130 mmHg
• Known or suspected CYP2D6 poor or intermediate metabolizer status
• eGFR <60 mL/min/1.73m2
• Known G6PD deficiency with atypical prior drug responses
• No prior stimulant exposure (first prescription ever)

Slower titration adds 2-4 weeks to the total time-to-optimal-dose but significantly reduces the risk of a hypertensive adverse event that could lead to premature discontinuation and reinforce a patient's hesitancy about stimulant therapy.

Pharmacogenomic Testing Access

Commercially available pharmacogenomic panels (GeneSight, Genomind, and others) routinely report CYP2D6 phenotype. Coverage by Medicaid and commercial plans varies by state. Where testing is accessible, the result can directly inform titration pace. PharmGKB has a Clinical Pharmacogenomics Implementation Consortium (CPIC) guideline for CYP2D6 and atomoxetine; no equivalent CPIC guideline exists yet for amphetamines, but the CYP2D6 phenotype still provides directional guidance about metabolism rate [4].

Addressing Historical and Structural Barriers

Efficacy gaps in clinical data are inseparable from the structural conditions that produced them. Black patients with ADHD are more likely to be referred for behavioral intervention before medication, to have their symptoms attributed to conduct disorder rather than ADHD, and to receive lower doses of stimulants once diagnosed, according to analyses of Medicaid prescription records [6]. Each of these patterns can produce an apparent "lower response" to medication even when the pharmacology is identical.

The Role of Therapeutic Alliance

A 2020 analysis in JAMA Psychiatry found that Black patients with any psychiatric diagnosis were significantly more likely to discontinue medication within 90 days than white patients, after controlling for symptom severity and insurance status [see source 6 for context]. Early discontinuation produces incomplete dose titration, which produces subtherapeutic effects, which confirm a clinician's (or patient's) expectation that the drug "doesn't work as well."

Prescribers treating Black patients should explicitly discuss this cycle at the initiation visit: the dose being started is not the therapeutic dose, several weeks of titration are expected, and early side effects at subtherapeutic doses do not predict what the drug will feel like at the correct dose.

Shared Decision-Making and Cultural Context

The American Academy of Child and Adolescent Psychiatry practice parameters state: "Clinicians should inquire about cultural beliefs regarding medication and mental health that may affect treatment adherence." [11] This is not a suggestion to make assumptions about any individual patient's beliefs. It is a prompt to open a conversation that many clinicians skip.

What Clinicians Should Document

Every chart note for a Black or African ancestry patient being initiated on lisdexamfetamine should include:

• Baseline systolic and diastolic blood pressure, pulse, weight
• Baseline creatinine/eGFR
• Family history of sudden cardiac death or early MI (first-degree relative before age 55 in males, 65 in females)
• G6PD status if previously tested
• CYP2D6 phenotype if pharmacogenomic testing has been performed
• Explicit note of the titration schedule planned and why

This documentation serves two purposes: it protects the patient by ensuring relevant variables are considered, and it creates the longitudinal dataset that the field currently lacks for understanding pharmacokinetic variation by ancestry.

A Note on the Evidence Gap and What Needs to Change

The single most important clinical fact in this article is also the most uncomfortable one. There is no adequately powered, pre-registered, ethnicity-stratified randomized controlled trial of lisdexamfetamine with Black and African ancestry patients as the primary analytic population. The absence of such a trial is a failure of the drug development and regulatory system, not evidence that the drug works equally well in everyone.

The FDA's 2020 guidance on enhancing diversity in clinical trials [12] calls for sponsors to enroll populations that reflect the diversity of the intended treatment population. For a drug with a 13.6% Black American addressable market, "approximately 9.8% Black enrollment with no pre-specified subgroup analysis" does not meet that standard.

As the HealthRX medical team reviewed the available literature for this article, no peer-reviewed publication was identified that reported a pre-specified, powered efficacy comparison of lisdexamfetamine between Black and non-Black participants. That finding is itself clinically meaningful and should inform how prescribers communicate uncertainty to patients.

Clinicians should tell patients directly: the best available evidence shows lisdexamfetamine is effective for ADHD and binge eating disorder, and the trial populations were not representative of patients of African ancestry, so individual monitoring and titration matter more than average population estimates.

The starting dose remains 30 mg once daily; the first blood pressure check after initiation should occur within 7 days.